Exchange: NASDAQ·Updated 07:58 PM EST

KYMR News

News
all
press releases
Kymera Therapeutics (NASDAQ:KYMR) Stock Crosses Below 50 Day Moving Average - What's Next?
Kymera Therapeutics (NASDAQ:KYMR) Shares Break Below 50-Day Moving Average - Here's Why...
MarketBeat
Kymera Therapeutics (NASDAQ:KYMR) Stock Crosses Below 50 Day Moving Average - What's Next?
Kymera Therapeutics (NASDAQ:KYMR) Shares Break Below 50-Day Moving Average - Here's Why...
MarketBeat
More News
Fisher Asset Management LLC raised its holdings in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 2,438.6% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 323,219 shares of the company's stoc...
MarketBeat
Axsome (AXSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
Kymera Therapeutics advances its targeted protein degradation pipeline, with KT-621 trials in atopic dermatitis and asthma marking key milestones amid competition in the field.
Zacks
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Kymera Therapeutics, Inc. (NASDAQ: KYMR) SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Kymera Therapeutics, Inc. (NASDAQ: KYMR)PR NewswireNEW YORK, Oct. 12, 2026NEW YORK, Oct. 12...
PR Newswire
The trades put some of Ark's better-known holdings on the sell side, including AMD, Alphabet, and SpaceX, while its genomics-focused ARK Genomic Revolution ETF continued to add to biotech companies.
Stocktwits
Kuehn Law Encourages Investors of Kymera Therapeutics, Inc. to Contact Law Firm Kuehn Law Encourages Investors of Kymera Therapeutics, Inc. to Contact Law FirmPR NewswireNEW YORK, Sept. 30, 2026NEW YORK, Sept. 30, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is...
PR Newswire
Kymera Therapeutics (KYMR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
KYMR advances KT-621 in atopic dermatitis and asthma, with earlier-than-expected AD data and potential phase III plans by mid-2027.
Zacks
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets

Advertisement|Remove ads.